NASDAQ:UPB

Upstream Bio (UPB) Stock Price, News & Analysis

Upstream Bio logo
$2.00 -0.08 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$2.02 +0.02 (+0.75%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Upstream Bio Stock (NASDAQ:UPB)

Advanced

Key Stats

Today's Range
$2.00
▼
$2.19
50-Day Range
$2.08
▼
$5.81
52-Week Range
$2.00
▼
$33.68
Volume
856,120 shs
Average Volume
906,898 shs
Market Capitalization
$109.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.67
Consensus Rating
Hold

Company Overview

Upstream Bio is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses.

Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps.

The company’s work is focused on drug development and clinical research; it does not have a marketed product portfolio.

AI Generated. May Contain Errors.

Upstream Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

UPB MarketRank™: 
3.492355992355 of 5 stars

Upstream Bio scored higher than 70% of companies evaluated by MarketBeat, and ranked 513th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Upstream Bio has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Upstream Bio has a consensus price target of $26.67, representing about 1,233.3% upside from its current price of $2.00.

  • Amount of Analyst Coverage

    Upstream Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about Upstream Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Upstream Bio are expected to grow in the coming year, from ($2.81) to ($2.63) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Upstream Bio is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Upstream Bio is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Upstream Bio has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.76% of the float of Upstream Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Upstream Bio has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Upstream Bio has recently decreased by 20.77%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Upstream Bio does not currently pay a dividend.

  • Dividend Growth

    Upstream Bio does not have a long track record of dividend growth.

  • News Sentiment

    Upstream Bio has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Upstream Bio this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for UPB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Upstream Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.46% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Upstream Bio has minimal institutional ownership at this time.

  • Read more about Upstream Bio's insider trading history.
Receive UPB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

UPB Stock News Headlines

HC Wainwright Increases Earnings Estimates for Upstream Bio
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Headlines

UPB Stock Analysis - Frequently Asked Questions

Upstream Bio's stock was trading at $27.15 at the beginning of the year. Since then, UPB shares have decreased by 92.6% and is now trading at $2.00.

Upstream Bio, Inc. (NASDAQ:UPB) issued its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by $0.02. The business earned $395 thousand during the quarter, compared to analyst estimates of $549 thousand. Upstream Bio had a negative net margin of 5,712.33% and a negative trailing twelve-month return on equity of 57.09%.

Upstream Bio (UPB) raised $200 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO.

Top institutional shareholders of Upstream Bio include Goldman Sachs Group Inc. (2.06%), State Street Corp (1.34%), Samsara Biocapital LLC (0.55%) and Jump Financial LLC (0.37%). Insiders that own company stock include Erez Chimovits, Ai Upstream Llc and Michael Gray.
View institutional ownership trends
.

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/10/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:UPB
Previous Symbol
NASDAQ:UPB
CIK
2022626
Fax
N/A
Employees
75
Year Founded
2021

Price Target and Rating

High Price Target
$50.00
Low Price Target
$9.00
Potential Upside/Downside
+1,233.3%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$143.44 million
Net Margins
-5,712.33%
Pretax Margin
-5,712.33%
Return on Equity
-57.09%
Return on Assets
-54.69%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
20.45
Quick Ratio
20.45

Sales & Book Value

Annual Sales
$2.87 million
Price / Sales
38.20
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.27 per share
Price / Book
0.47

Miscellaneous

Outstanding Shares
54,811,000
Free Float
45,789,000
Market Cap
$109.62 million
Optionable
Optionable
Beta
1.60

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:UPB) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners